Business Wire

Biocodex Group Strengthens Its Position in the US Market With the Acquisition of Hilma, a Fast-Growing Natural Remedies Start-Up

Share

Biocodex, an expert in microbiota and women's health, announces that it has acquired a majority stake in Hilma, a start-up specializing in natural remedies in the United States. This acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women's health segments of the US market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005739/en/

Hilma, founded by entrepreneurs Hilary Quartner, Nina Mullen, and Lily Galef, launched in January 2020 with the ambition to reimagine the medicine cabinet with effective, natural alternatives to OTC products. Hilma makes natural remedies for digestive issues, sleep, immune support, and more. Since launch, the digitally native brand has built a strong community around its best-selling digestive portfolio. They have expanded their product line to encompass everything from bloating to occasional constipation and have become a fixture in the digestive aisle at Target, among other retailers.

The Biocodex Group has been present in the US for over 20 years and is a leader in the pharmacy market with its Florastor® brand in the probiotics category. Through this acquisition, the Group aims to strengthen its position in this segment and launch its women's health activity in order to double its turnover by 2027.

Julien Dureisseix, GM of the US subsidiary, is delighted with this acquisition: "Behind Hilma, there is a simple observation: a new generation of consumers has high expectations for natural and effective products." Nicolas Coudurier, CEO of Biocodex, adds: "Hilma and Biocodex share the same goal: to be as close as possible to consumers expectations and to respond to the growing need for reliable, effective and scientifically proven natural solutions in the medicine cabinet. I am very pleased to welcome a talented team whose entrepreneurial vision and digital expertise will be invaluable in strengthening our presence in the North American market."

Nina Mullen, Co-CEO of Hilma says, “Our partnership with The Biocodex Group will enable Hilma to rapidly scale our omnichannel retail strategy, reach new audiences, and develop new products.” Hilary Quartner, Co-CEO adds, “We are thrilled to join the Biocodex family, as they share our core values of commitment to scientifically backed, natural healthcare, and building a sustainable future.” “We look forward to learning from each other and exponentially growing Hilma and The Biocodex Group brands in the US.”, notes Lily Galef, Chief Brand Officer.

ADDITIONAL INFORMATION
About Biocodex

Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Orphan diseases; Women’s health. With 1,600 employees, Biocodex generated net revenues of €418 million in 2021, including 42% in France and 58% internationally. The group is present in 124 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.

About Hilma

Hilma makes natural remedies that actually work for health issues like digestion, head tension, immune support and more. Hilma’s remedies are made with powerful herbs and minerals, formulated with a team of doctors, and backed by clinical research. Unlike most over-the-counter options, Hilma is made without drugs, dyes, fillers, preservatives, or artificial sweeteners. The company makes natural remedies accessible to a mainstream customer, who has embraced natural products in food, beauty, and household items, and is looking for an effective natural option for their medicine cabinet. Hilma is entirely female-founded and led. Hilma is an omnichannel brand, sold DTC on hilma.co as well as in 750+ stores, including Target, Grove Collaborative, Thrive Market, Juice Press, and Amazon.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact:
Françoise Vapillon-Burlet
f.vapillon-burlet@biocodex.com
T: +33 1 41 24 30 84

Hilma contact:
Lily Galef
lily@hilma.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble™9.12.2022 06:30:00 EET | Press release

Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble ™ is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumble will release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005292/en/ Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble , fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer a

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the

TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release

TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu

Verisign Reports Internet Has 349.9 Million Domain Name Registrations at the End of the Third Quarter of 20228.12.2022 23:57:00 EET | Press release

VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the third quarter of 2022 closed with 349.9 million domain name registrations across all top-level domains, a decrease of 1.6 million domain name registrations, or 0.4%, compared to the second quarter of 2022.1,2 Domain name registrations have increased by 11.5 million, or 3.4%, year over year.1,2 The .com and .net TLDs had a combined total of 174.2 million domain name registrations in the domain name base3 at the end of the third quarter of 2022, a decrease of 0.2 million domain name registrations, or 0.1%, compared to the second quarter of 2022. The .com and .net TLDs had a combined increase of 2.1 million domain name registrations, or 1.2%, year over year. As of Sept. 30, 2022, the .com domain name base totaled 160.9 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net domain

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom